Pseudomonas aeruginosa septicaemia in burns

Affiliations


Abstract

Out of 1415 patients treated as inpatients at Al-Babtain Center for Burns and Plastic Surgery, Ibn Sina Hospital, Kuwait spanning over a period of 6 years from June 1992 to June 1998, 102 developed clinically and microbiologically proven septicaemia. Only 15 out of them had either single or multiple episodes of septicaemia due to Pseudomonas aeruginosa and were studied during their stay in the hospital. Five of them were males and 10 females, with a mean age of 26 years (range 3-51 years) and mean total body surface area of burns (TBSA) of 66% (range 25-90%). All of them had flame burns and resuscitation was found to be difficult in eight patients either due to delayed hospitalization or accompanied inhalation injury. Seven patients were intubated, four due to inhalation injury and three for septicaemic complications. Among the 15 patients under study, a total of 36 septicaemic episodes were detected of which 21 were due to P. aeruginosa. This organism was found in the first episodes in nine patients, in second episodes in six, in third episodes in three and fourth, fifth and sixth episodes in one patient, each at a variable postburn day. Ten patients had 38 sessions of excision and skin grafting, six of them survived. Nine of the 15 patients under study died due to septicaemia, but only six of them had P. aeruginosa as the last isolate. Except for one, all patients had > 40% TBSA burn, two had difficult resuscitation and four were intubated. The day of death varied between 3 to 52 days postburn (mean 19 days). This study showed that females with flame burns are susceptible to P. aeruginosa septicaemia. Difficult resuscitation and intubation also proved to be important risk factors. Septicaemia could occur quite early in the postburn days and the mortality due to this organism was quite high. Early excision and grafting with other effective management may result in a better outcome.


Similar articles

Staphylococcal septicaemia in burns.

Gang RK, Sanyal SC, Bang RL, Mokaddas E, Lari AR.Burns. 2000 Jun;26(4):359-66. doi: 10.1016/s0305-4179(99)00170-9.PMID: 10751704

Burn septicaemia: an analysis of 79 patients.

Bang RL, Gang RK, Sanyal SC, Mokaddas E, Ebrahim MK.Burns. 1998 Jun;24(4):354-61. doi: 10.1016/s0305-4179(98)00022-9.PMID: 9688202

Burn septicaemia in Kuwait: associated demographic and clinical factors.

Bang RL, Sharma PN, Sanyal SC, Bang S, Ebrahim MK.Med Princ Pract. 2004 May-Jun;13(3):136-41. doi: 10.1159/000076952.PMID: 15073425

Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s.

Maschmeyer G, Braveny I.Eur J Clin Microbiol Infect Dis. 2000 Dec;19(12):915-25. doi: 10.1007/s100960000410.PMID: 11205628 Review.

Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology.

Tacconelli E, Tumbarello M, Bertagnolio S, Citton R, Spanu T, Fadda G, Cauda R.Emerg Infect Dis. 2002 Feb;8(2):220-1. doi: 10.3201/eid0802.010121.PMID: 11897080 Free PMC article. Review. No abstract available.


Cited by

Point-of-critical-care diagnostics for sepsis enabled by multiplexed micro and nanosensing technologies.

Ashley BK, Hassan U.Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Sep;13(5):e1701. doi: 10.1002/wnan.1701. Epub 2021 Mar 1.PMID: 33650293 Free PMC article. Review.

Monophosphoryl Lipid a Attenuates Multiorgan Dysfunction During Post-Burn Pseudomonas Aeruginosa Pneumonia in Sheep.

Fukuda S, Ihara K, Bohannon JK, Hernandez A, Patil NK, Luan L, Stothers C, Stark R, Prough DS, Herndon DN, Sherwood ER, Enkhbaatar P.Shock. 2020 Mar;53(3):307-316. doi: 10.1097/SHK.0000000000001364.PMID: 31045990 Free PMC article.

Bacteriology of the burn wound at the Bai Jerbai Wadia hospital for children, Mumbai, India-A 21 year study of predominant Pseudomonas species.

Srinivasan S, Saldanha J, Abhyankar S, Patil A, Vartak AM.Int J Burns Trauma. 2018 Aug 20;8(4):98-105. eCollection 2018.PMID: 30245914 Free PMC article.

How to manage Pseudomonas aeruginosa infections.

Bassetti M, Vena A, Croxatto A, Righi E, Guery B.Drugs Context. 2018 May 29;7:212527. doi: 10.7573/dic.212527. eCollection 2018.PMID: 29872449 Free PMC article. Review.

Core-shell magnetic nanoparticles display synergistic antibacterial effects against Pseudomonas aeruginosa and Staphylococcus aureus when combined with cathelicidin LL-37 or selected ceragenins.

Niemirowicz K, Piktel E, Wilczewska AZ, Markiewicz KH, Durnaś B, Wątek M, Puszkarz I, Wróblewska M, Niklińska W, Savage PB, Bucki R.Int J Nanomedicine. 2016 Oct 19;11:5443-5455. doi: 10.2147/IJN.S113706. eCollection 2016.PMID: 27799768 Free PMC article.


KMEL References